Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis.
McCall D, Abuasab T, Rodriguez-Sevilla JJ, Mohamed SF, Patnaik A, Devireddy K, Arani N, Sheikh I, Jamshidi R, Gibson A, Roth M, Nuñez C, Garcia M, Chien KS, Loghavi S, Pierce SA, Sasaki K, Issa G, Cuglievan B, Kantarjian H, Garcia-Manero G. McCall D, et al. Among authors: abuasab t. Leuk Res. 2024 Sep;144:107563. doi: 10.1016/j.leukres.2024.107563. Epub 2024 Aug 20. Leuk Res. 2024. PMID: 39178611
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Haddad FG, et al. Among authors: abuasab t. JCO Oncol Pract. 2024 Jul 16:OP2400027. doi: 10.1200/OP.24.00027. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39013130
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. Abuasab T, et al. Leuk Lymphoma. 2024 Sep;65(9):1344-1349. doi: 10.1080/10428194.2024.2347539. Epub 2024 May 2. Leuk Lymphoma. 2024. PMID: 38696743
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Abuasab T, et al. Am J Hematol. 2024 Jul;99(7):1434-1436. doi: 10.1002/ajh.27333. Epub 2024 Apr 13. Am J Hematol. 2024. PMID: 38613831 No abstract available.
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Bazinet A, et al. Among authors: abuasab t. Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4. Lancet Haematol. 2024. PMID: 38452788 Clinical Trial.
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies.
Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Bataller A, et al. Among authors: abuasab t. Haematologica. 2024 Jan 1;109(1):293-297. doi: 10.3324/haematol.2023.283705. Haematologica. 2024. PMID: 37646654 Free PMC article. No abstract available.
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Desikan SP, et al. Among authors: abuasab t. Am J Hematol. 2023 Jun;98(6):E142-E144. doi: 10.1002/ajh.26907. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36877196 Free article. No abstract available.
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Senapati J, et al. Among authors: abuasab t. Am J Hematol. 2023 Mar;98(3):E53-E56. doi: 10.1002/ajh.26811. Epub 2022 Dec 24. Am J Hematol. 2023. PMID: 36565294 Free article. No abstract available.